STOCKHOLM–(Business Wire)–SciBase, a Swedish medtech company that develops and markets a new
technology for early detection of malignant melanoma, together with its
partner KTH Royal Institute of Technology, have been granted 3.9 MSEK
from Vinnova's 'Smarter Electronic Systems' program fund. The project is
for the development of a minimized and modular next generation of
SciBase's product Nevisense.
The project's objective is to minimize the size of measurement
electronics, which is essential to the next generation of Nevisense.
Vinnova's explanatory statement for approving SciBase's application:
"The project strengthens SciBase's competitiveness and the niche market
for embedded systems in medical technology. The project received
especially good marks in regards to the main criteria Potential and
Practicability."
"The development of minimized measuring electronics is key for the next
generation of Nevisense. We are very pleased with Vinnova's support and
the funding allows us to start working on the project in the next
quarter," says Fredrik Goldkuhl, Head of Research and Development at
SciBase.
SciBase's partner in the project is the Integrated Circuits and Systems
Department at KTH Royal Institute of Technology in Kista, Stockholm.
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in
Stockholm that has developed a unique point-of-care device for the
accurate detection of malignant melanoma. Its product, Nevisense, helps
doctors to detect malignant melanoma, the most dangerous type of skin
cancer. SciBase was founded by Stig Ollmar, Associate Professor at The
Karolinska Institute in Stockholm, Sweden. Nevisense is based on
substantial research and has achieved excellent results in the largest
clinical study ever conducted on the detection of malignant melanoma.
Nevisense is CE marked in Europe, has TGA approval in Australia, and is
awaiting FDA clearance in the United States. Nevisense is based on a
method called Electrical Impedance Spectroscopy (EIS), which uses the
varying electrical properties of human tissue to categorize cellular
structures and thereby detect malignancies. SciBase is listed on Nasdaq
First North (“SCIB”). Avanza is Certified Adviser. Further information
is available on www.scibase.com.
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150602007173/en/
SciBase
Simon Grant, CEO
Phone: +46 72 887 43 99
Email: simon.grant@scibase.com
No comments:
Post a Comment